{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-001693","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2025-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.926402+00:00","generated_at":"2026-05-24T11:42:18.158526+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Xenetic Biosciences FY2024 net loss $4.0M; cash $6.2M; advancing DNase I to IND","bullets":["Net loss ~$4.0M for FY2024; R&D expenses fell 5.9% to $3.3M from $3.5M YoY.","Royalty payments from Takeda sublicense ~$2.5M, relatively flat vs. prior year.","Cash and cash equivalents at year-end ~$6.2M.","Continuing DNase I development toward IND/Phase 1 for pancreatic carcinoma.","Entered Clinical Trial Services Agreement with PeriNess for exploratory studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-001693","json":"https://secwatch.observer/filing/0001683168-25-001693.json","markdown":"https://secwatch.observer/filing/0001683168-25-001693.md","text":"https://secwatch.observer/filing/0001683168-25-001693.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316825001693/0001683168-25-001693-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316825001693/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T11:42:18.158526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}